No results for ‘’
Strides Pharma Science Ltd
₹1223.10
(0.97%)
Fri, 25 Sept 2026, 11:27 pm
Health Technology
Pharmaceuticals: Major
24.5KStrides Pharma Science Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 25.49 | 39.26 | 0 | 3.62 | 12.16 | 18.28 | 10.46 | 8.31 | 0 | 4530 | 92.09 | 54.19 | 0 | 80.77 | 119.66 | 29.77 | 0 | 0 | 0 | 15.19 |
| Price to book ratio | 4.15 | 3.89 | 4.35 | 0.98 | 1.23 | 2.02 | 1.71 | 3.18 | 2.29 | 6.14 | 3.66 | 3.57 | 2.44 | 1.59 | 1.14 | 2.73 | 1.32 | 1.17 | 3.38 | 2.42 |
| Price to sales ratio | 2.33 | 2.01 | 1.36 | 0.46 | 1.01 | 1.32 | 0.93 | 3.12 | 2.29 | 5.89 | 3.16 | 3.56 | 2.11 | 1.99 | 1.08 | 2.31 | 1.02 | 0.70 | 1.86 | 1.38 |
| Price to cash flow ratio | 27.07 | 22.19 | 23.86 | 7.24 | 0 | 10.86 | 5.02 | 0 | 0 | 117.50 | 0 | 76.66 | 0 | 0 | 50.55 | 21.71 | 0 | 0 | 16.81 | 13.47 |
| Enterprise value | 1638Cr | 2107Cr | 2140Cr | 1944Cr | 2990Cr | 3484Cr | 4702Cr | 8375Cr | 2289Cr | 7252Cr | 11505Cr | 13095Cr | 8076Cr | 6798Cr | 4835Cr | 9682Cr | 5972Cr | 5201Cr | 9298Cr | 7864Cr |
| Enterprise value to EBITDA ratio | 15.34 | 18.15 | 0 | 9.87 | 16 | 14.90 | 11.06 | 15.42 | 16.98 | 30.14 | 27.47 | 24.72 | 19.89 | 34.28 | 13.51 | 18.74 | 0 | 14.20 | 18.06 | 11.08 |
| Debt to equity ratio | 1.41 | 1.46 | 4.62 | 3.13 | 1.75 | 1.57 | 1.87 | 0.79 | 0.54 | 0.78 | 1.33 | 1.35 | 1.02 | 1.22 | 0.88 | 0.85 | 1.28 | 1.37 | 1.18 | 0.74 |
| Return on equity % | 18.75 | 11.69 | -15.58 | 31.20 | 17.60 | 11.59 | 16.91 | 49.81 | -12.28 | 0.15 | 6.93 | 8.64 | 2.09 | 3.29 | 1.90 | 9.60 | -17.92 | -9.68 | -5.54 | 17.33 |
Strides Pharma Science Ltd Ratios
The Strides Pharma Science Ltd Ratios page provides a complete fundamental analysis of Strides Pharma Science Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Strides Pharma Science Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Strides Pharma Science Ltd (NSE: STAR, BSE: 532531) is currently trading at ₹1223.10, with a market capitalization of ₹11245.07Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Strides Pharma Science Ltd remains a key stock for fundamental analysis using Strides Pharma Science Ltd Ratios.
Strides Pharma Science Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Strides Pharma Science Ltd P/E ratio currently stands at 15.19, making it one of the most tracked metrics in Strides Pharma Science Ltd Ratios.
Historically, the Strides Pharma Science Ltd P/E ratio has shown strong fluctuations:
- 2024: 15.19
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 29.77
The rising Strides Pharma Science Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Strides Pharma Science Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.42.
Historical P/B trend:
- 2024: 2.42
- 2023: 3.38
- 2022: 1.17
- 2021: 1.32
Strides Pharma Science Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Strides Pharma Science Ltd P/S ratio currently stands at 1.38, an important part of Strides Pharma Science Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.38
- 2023: 1.86
- 2022: 0.70
- 2021: 1.02
A stable or declining Strides Pharma Science Ltd P/S ratio indicates cautious market sentiment.
Strides Pharma Science Ltd Price to Cash Flow Ratio (P/CF)
The Strides Pharma Science Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 13.47.
Historical Strides Pharma Science Ltd Price to Cash Flow Ratio:
- 2024: 13.47
- 2023: 16.81
- 2022: 0
- 2021: 0
- 2020: 21.71
The declining Strides Pharma Science Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Strides Pharma Science Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Strides Pharma Science Ltd EV currently stands at ₹7864Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 7864Cr
- 2023: 9298Cr
- 2022: 5201Cr
- 2021: 5972Cr
Strides Pharma Science Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Strides Pharma Science Ltd EV/EBITDA ratio is currently 11.08, a key metric in Strides Pharma Science Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 11.08
- 2023: 18.06
- 2022: 14.20
- 2021: 0
Stable Strides Pharma Science Ltd EV/EBITDA indicates balanced valuation.
Strides Pharma Science Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Strides Pharma Science Ltd D/E ratio is currently 0.74, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.74
- 2023: 1.18
- 2022: 1.37
- 2021: 1.28
Strides Pharma Science Ltd maintains moderate leverage with manageable risk.
Return on Equity (ROE %)
The Strides Pharma Science Ltd ROE currently stands at 17.33%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 17.33
- 2023: -5.54
- 2022: -9.68
- 2021: -17.92
Strides Pharma Science Ltd maintains stable profitability levels.
Strides Pharma Science Ltd Ratios Analysis Summary
The Strides Pharma Science Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Strides Pharma Science Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Strides Pharma Science Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.